S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13

Hill-Rom Holdings, Inc. (NYSE:HRC) Receives Average Recommendation of "Hold" from Analysts

Thursday, November 25, 2021 | MarketBeat

Shares of Hill-Rom Holdings, Inc. (NYSE:HRC) have received an average rating of "Hold" from the six analysts that are presently covering the firm, Marketbeat reports. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $143.80.

HRC has been the subject of several recent research reports. Bank of America downgraded Hill-Rom from a "buy" rating to a "neutral" rating and set a $130.00 price objective for the company. in a report on Tuesday, August 10th. KeyCorp downgraded Hill-Rom from an "overweight" rating to a "sector weight" rating in a report on Wednesday, September 8th. Morgan Stanley downgraded Hill-Rom from an "overweight" rating to an "equal weight" rating and boosted their price objective for the company from $148.00 to $156.00 in a report on Sunday, September 19th. Robert W. Baird downgraded Hill-Rom from an "outperform" rating to a "neutral" rating and boosted their price objective for the company from $150.00 to $156.00 in a report on Friday, September 3rd. Finally, Stifel Nicolaus downgraded Hill-Rom from a "buy" rating to a "hold" rating and set a $155.00 price objective for the company. in a report on Friday, November 5th.

In other Hill-Rom news, SVP Mary Kay Ladone sold 2,018 shares of the company's stock in a transaction on Thursday, November 11th. The stock was sold at an average price of $155.14, for a total value of $313,072.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 0.69% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of HRC. Arizona State Retirement System lifted its holdings in Hill-Rom by 0.4% during the 3rd quarter. Arizona State Retirement System now owns 18,105 shares of the medical technology company's stock worth $2,716,000 after purchasing an additional 66 shares in the last quarter. Ifrah Financial Services Inc. lifted its holdings in Hill-Rom by 3.4% during the 2nd quarter. Ifrah Financial Services Inc. now owns 2,300 shares of the medical technology company's stock worth $261,000 after purchasing an additional 76 shares in the last quarter. Rockefeller Capital Management L.P. lifted its holdings in Hill-Rom by 20.2% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 453 shares of the medical technology company's stock worth $67,000 after purchasing an additional 76 shares in the last quarter. MCF Advisors LLC lifted its holdings in Hill-Rom by 78.3% during the 3rd quarter. MCF Advisors LLC now owns 205 shares of the medical technology company's stock worth $31,000 after purchasing an additional 90 shares in the last quarter. Finally, Advisor Group Holdings Inc. lifted its holdings in Hill-Rom by 1.5% during the 2nd quarter. Advisor Group Holdings Inc. now owns 6,135 shares of the medical technology company's stock worth $698,000 after purchasing an additional 93 shares in the last quarter. 76.45% of the stock is currently owned by hedge funds and other institutional investors.

Shares of HRC opened at $155.50 on Thursday. Hill-Rom has a 52-week low of $93.34 and a 52-week high of $156.22. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.05 and a current ratio of 1.38. The business's 50 day moving average price is $152.89 and its two-hundred day moving average price is $133.81. The firm has a market cap of $10.27 billion, a PE ratio of 41.80 and a beta of 0.54.

Hill-Rom (NYSE:HRC) last issued its quarterly earnings results on Friday, November 5th. The medical technology company reported $1.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.47 by $0.20. Hill-Rom had a return on equity of 23.07% and a net margin of 8.23%. The firm had revenue of $797.90 million for the quarter, compared to analyst estimates of $752.97 million. During the same period in the previous year, the firm earned $1.17 earnings per share. The company's revenue was up 13.1% compared to the same quarter last year. Research analysts predict that Hill-Rom will post 6.44 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 31st. Shareholders of record on Wednesday, December 15th will be paid a $0.24 dividend. The ex-dividend date is Tuesday, December 14th. This represents a $0.96 dividend on an annualized basis and a yield of 0.62%. Hill-Rom's dividend payout ratio (DPR) is presently 25.81%.

About Hill-Rom

Hill-Rom Holdings, Inc operates as a medical technology company. The firm focuses on patient care solutions that improve clinical and economic outcomes. It operates through the following segments: Patient Support System, Front Line Care and Surgical Solutions. The Patient Support Systems segment provides bed frames and surfaces, mobility and clinical workflow solutions.

Featured Story: How to interpret Moving Average Convergence Divergence (MACD)

Analyst Recommendations for Hill-Rom (NYSE:HRC)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $1,000 in Hill-Rom right now?

Before you consider Hill-Rom, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hill-Rom wasn't on the list.

While Hill-Rom currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

 


Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.